News & Updates

Low-dose minocycline formulation works against papulopustular rosacea

20 Mar 2025

The low-dose modified formulation of minocycline hydrochloride, DFD-29, appears to be safe and efficacious in the treatment of adults with moderate to severe papulopustular rosacea, according to data from the phase III MVOR-1 and MVOR-2 trials.

Low-dose minocycline formulation works against papulopustular rosacea

20 Mar 2025

Dupilumab eases itch, disease activity in chronic spontaneous urticaria

16 Mar 2025 by

Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.

Dupilumab eases itch, disease activity in chronic spontaneous urticaria

16 Mar 2025

Ruxolitinib cream shows benefit in patients with AD regardless of age

15 Mar 2025 by

Twice-daily application of ruxolitinib cream appears effective and well tolerated in the treatment of mild-to-moderate atopic dermatitis (AD) regardless of age, based on a pooled analysis of three phase III trials presented at AAAAI/WAO 2025.

Ruxolitinib cream shows benefit in patients with AD regardless of age

15 Mar 2025

Omalizumab continues to OUtMATCH OIT in updated analysis

14 Mar 2025 by

Omalizumab remains superior to oral immunotherapy (OIT) for the treatment of multi-food allergies with fewer adverse effects in Stage 2 of the NIH*-sponsored phase III OUtMATCH** study, the first head-to-head trial comparing the two treatments.

Omalizumab continues to OUtMATCH OIT in updated analysis

14 Mar 2025

HPV vaccines useful for managing actinic keratosis

11 Mar 2025

Standard α-HPV vaccination appears to reduce the burden of actinic keratosis (AK) in individuals with multiple lesions, according to the VAXAK trial.

HPV vaccines useful for managing actinic keratosis

11 Mar 2025

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025 by

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

07 Mar 2025

COVID-19 ups AIBD risk, but vaccination helps

06 Mar 2025 by

Individuals with COVID-19 infection are at higher risk of autoimmune blistering disease (AIBD), but vaccination helps reduce such risk, suggests a study.

COVID-19 ups AIBD risk, but vaccination helps

06 Mar 2025

HPV infection ups risk of new-onset hidradenitis suppurativa

05 Mar 2025

Infection with the human papillomavirus (HPV) contributes to an increased risk of developing hidradenitis suppurativa (HS), indicating a potential association, reveals a study.

HPV infection ups risk of new-onset hidradenitis suppurativa

05 Mar 2025

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

05 Mar 2025

Treatment with 5-fluorouracil (5-FU) 5% cream tends to end in failure with shorter treatment duration and larger lesion size in patients with squamous cell carcinoma in situ (SCCis), a study has shown.

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

05 Mar 2025

Dietary fibre, probiotics: Allies in the fight against eczema and allergies

22 Feb 2025 by

A diet rich in fibre appears to offer some protection against atopic dermatitis and a common allergy triggered by house dust mites in Asians, with the risks further mitigated by combining dietary fibre with probiotics, as reported in a study.

Dietary fibre, probiotics: Allies in the fight against eczema and allergies

22 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

Low-dose minocycline formulation works against papulopustular rosacea

Low-dose minocycline formulation works against papulopustular rosacea

Dupilumab eases itch, disease activity in chronic spontaneous urticaria

Dupilumab eases itch, disease activity in chronic spontaneous urticaria

Ruxolitinib cream shows benefit in patients with AD regardless of age

Ruxolitinib cream shows benefit in patients with AD regardless of age

Omalizumab continues to OUtMATCH OIT in updated analysis

Omalizumab continues to OUtMATCH OIT in updated analysis

HPV vaccines useful for managing actinic keratosis

HPV vaccines useful for managing actinic keratosis

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

Benralizumab offers durability in EGPA, adds value to patients switched from mepolizumab

COVID-19 ups AIBD risk, but vaccination helps

COVID-19 ups AIBD risk, but vaccination helps

HPV infection ups risk of new-onset hidradenitis suppurativa

HPV infection ups risk of new-onset hidradenitis suppurativa

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

Dietary fibre, probiotics: Allies in the fight against eczema and allergies

Dietary fibre, probiotics: Allies in the fight against eczema and allergies